Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 330 versus VITUZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 330 versus VITUZ.
FULVICIN P/G 330 vs VITUZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
Vituz is an epidermal growth factor receptor (EGFR) inhibitor that binds to the tyrosine kinase domain, blocking downstream signaling pathways involved in cell proliferation and survival.
330 mg orally once daily with fatty meal to enhance absorption.
400 mg orally every 8 hours for 5 days; initiate within 48 hours of symptom onset.
None Documented
None Documented
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
The terminal elimination half-life is 12-15 hours in patients with normal renal function, allowing twice-daily dosing. In moderate renal impairment (CrCl 30-50 mL/min), half-life extends to 20-28 hours; in severe impairment (CrCl <30 mL/min), it exceeds 40 hours.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
VITUZ (vitluzolamide) is primarily excreted via renal elimination as unchanged drug (45-55%) and as the major inactive metabolite M1 (20-30%). Biliary/fecal excretion accounts for 15-20%, primarily as M1. Less than 5% is eliminated via other routes.
Category C
Category C
Antifungal
Antifungal